P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation

Ernesto Yagüe, Angel L. Armesilla, Georgina B. Harrison, James I. Elliott, Alessandro Sardini, Christopher F. Higgins, Selina Raguz

Journal of Biological Chemistry · 2003 · 126 citations · 55 references

DOIFull text

Open access

Concepts

Abstract

Multidrug resistance in acute myeloid leukemia is often conferred by overexpression of P-glycoprotein, encoded by the MDR1 gene. We have characterized the key regulatory steps in the development of multidrug resistance in K562 myelogenous leukemic cells. Unexpectedly, up-regulation ofMDR1 levels was not due to transcriptional activation but was achieved at two distinct post-transcriptional steps, mRNA turnover and translational regulation. The short-lived (half-life 1 h) MDR1 mRNA of naı̈ve cells (not exposed to drugs) was stabilized (half-life greater than 10 h) following short-term drug exposure. However, this stabilized mRNA was not associated with translating polyribosomes and did not direct P-glycoprotein synthesis. Selection for drug resistance, by long-term exposure to drug, led to resistant lines in which the translational block was overcome such that the stabilized mRNA was translated and P-glycoprotein expressed. The absence of a correlation between steady-state MDR1 mRNA and P-glycoprotein levels was not restricted to K562 cells but was found in other lymphoid cell lines. These findings have implications for the avoidance or reversal of multidrug resistance in the clinic. Multidrug resistance in acute myeloid leukemia is often conferred by overexpression of P-glycoprotein, encoded by the MDR1 gene. We have characterized the key regulatory steps in the development of multidrug resistance in K562 myelogenous leukemic cells. Unexpectedly, up-regulation ofMDR1 levels was not due to transcriptional activation but was achieved at two distinct post-transcriptional steps, mRNA turnover and translational regulation. The short-lived (half-life 1 h) MDR1 mRNA of naı̈ve cells (not exposed to drugs) was stabilized (half-life greater than 10 h) following short-term drug exposure. However, this stabilized mRNA was not associated with translating polyribosomes and did not direct P-glycoprotein synthesis. Selection for drug resistance, by long-term exposure to drug, led to resistant lines in which the translational block was overcome such that the stabilized mRNA was translated and P-glycoprotein expressed. The absence of a correlation between steady-state MDR1 mRNA and P-glycoprotein levels was not restricted to K562 cells but was found in other lymphoid cell lines. These findings have implications for the avoidance or reversal of multidrug resistance in the clinic. multidrug resistance reverse transcription 12-O-tetradecanoylphorbol-13-acetate threshold cycle luciferase Epstein-Barr virus MDR1 is the most common impediment to successful chemotherapy for a variety of cancers (1Gottesman M.M. Fojo T. Bates S.E. Nat. Rev. Cancer. 2002; 2: 48-58Crossref PubMed Scopus (4443) Google Scholar). The most frequent form of drug resistance in relapsed acute leukemia is overexpression of P-glycoprotein (2McKenna S.L. Padua R.A. Br. J. Haematol. 1997; 96: 659-674Crossref PubMed Scopus (77) Google Scholar, 3Ivy S.P. Olshefski R.S. Taylor B.J. Patel K.M. Reaman G.H. Blood. 1996; 88: 309-318Crossref PubMed Google Scholar). P-glycoprotein is a member of the ATP-binding cassette superfamily of active transporters and functions as an energy-dependent efflux pump that reduces the intracellular concentration of cytotoxic compounds and, hence, their toxicity. P-glycoprotein has a broad substrate specificity and can confer resistance to a wide range of different cytotoxic compounds (4Gottesman M.M. Pastan I. Annu. Rev. Biochem. 1993; 62: 385-427Crossref PubMed Scopus (3547) Google Scholar). Most pre-clinical and clinical efforts to overcome MDR aim to modulate P-glycoprotein activity. However, clinical trials of compounds that inhibit P-glycoprotein activity have had limited success and led to adverse pharmacokinetic side effects (1Gottesman M.M. Fojo T. Bates S.E. Nat. Rev. Cancer. 2002; 2: 48-58Crossref PubMed Scopus (4443) Google Scholar). It may, therefore, be more appropriate to target MDR1 expression. Indeed,MDR1 transcription has been targeted with Ecteinascidin 743 in pre-clinical studies (5Jin S. Gorfajn B. Faircloth G. Scotto K.W. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 6775-6779Crossref PubMed Scopus (201) Google Scholar) and more recently by modulation of the nuclear receptor SXR (6Synold T.W. Dussault I. Forman B.M. Nat. Med. 2001; 7: 584-590Crossref PubMed Scopus (748) Google Scholar). Strategies involving antisense and transcriptional decoy (7Marthinet E. Divita G. Bernaud J. Rigal D. Baggetto L.G. Gene Ther. 2000; 7: 1224-1233Crossref PubMed Scopus (36) Google Scholar) and the use of anti-MDR1 mRNA hammerhead ribozymes have also been suggested (8Wang F.S. Kobayashi H. Liang K.W. Holland J.F. Ohnuma T. Hum. Gene Ther. 1999; 10: 1185-1195Crossref PubMed Scopus (33) Google Scholar). Stresses such as short-term exposure to cytotoxic drugs results in the up-regulation of MDR1 mRNA levels in many cell lines (9Hu Z. Jin S. Scotto K.W. J. Biol. Chem. 2000; 275: 2979-2985Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar, 10Madden M.J. Morrow C.S. Nakagawa M. Goldsmith M.E. Fairchild C.R. Cowan K.H. J. Biol. Chem. 1993; 268: 8290-8297Abstract Full Text PDF PubMed Google Scholar, 11Chaudhary P.M. Roninson I.B. J. Natl. Cancer Inst. 1993; 85: 632-639Crossref PubMed Scopus (360) Google Scholar, 12Thorgeirsson S.S. Huber B.E. Sorrell S. Fojo A. Pastan I. Gottesman M.M. Science. 1987; 236: 1120-1122Crossref PubMed Scopus (247) Google Scholar, 13Marino P.A. Gottesman M.M. Pastan I. Cell Growth Differ. 1990; 1: 57-62PubMed Google Scholar) and in human metastatic sarcomas in vivo (14Abolhoda A. Wilson A.E. Ross H. Danenberg P.V. Burt M. Scotto K.W. Clin Cancer Res. 1999; 5: 3352-3356PubMed Google Scholar). This is frequently due to transcriptional activation of the MDR1gene and has been reported in many cell lines after different physical and chemical stimulations and in cells selected for resistance to a variety of cytotoxic drugs (5Jin S. Gorfajn B. Faircloth G. Scotto K.W. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 6775-6779Crossref PubMed Scopus (201) Google Scholar, 9Hu Z. Jin S. Scotto K.W. J. Biol. Chem. 2000; 275: 2979-2985Abstract Full Text Full Text PDF PubMed Scopus (134) Google Scholar, 10Madden M.J. Morrow C.S. Nakagawa M. Goldsmith M.E. Fairchild C.R. Cowan K.H. J. Biol. Chem. 1993; 268: 8290-8297Abstract Full Text PDF PubMed Google Scholar, 15Vilaboa N.E. Galan A. Troyano A. de Blas E. Aller P. J. Biol. Chem. 2000; 275: 24970-24976Abstract Full Text Full Text PDF PubMed Scopus (122) Google Scholar, 16Chin K.V. Tanaka S. Darlington G. Pastan I. Gottesman M.M. J. Biol. Chem. 1990; 265: 221-226Abstract Full Text PDF PubMed Google Scholar). In cell lines selected for drug resistance, increased MDR1 gene expression is also the result of amplification of the MDR1 locus and the appearance of self-replicating episomes (4Gottesman M.M. Pastan I. Annu. Rev. Biochem. 1993; 62: 385-427Crossref PubMed Scopus (3547) Google Scholar). Gene rearrangements that constitutively activate MDR1 transcription have also been associated with refractory acute lymphocytic leukemia (17Knutsen T. Mickley L.A. Ried T. Green E.D. du Manoir S. Schrock E. Macville M. Ning Y. Robey R. Polymeropoulos M. Torres R. Fojo T. Genes Chromosomes Cancer. 1998; 23: 44-54Crossref PubMed Scopus (70) Google Scholar, 18Mickley L.A. Spengler B.A. Knutsen T.A. Biedler J.L. Fojo T. J. Clin. Invest. 1997; 99: 1947-1957Crossref PubMed Scopus (93) Google Scholar). Although regulation due to changes in the MDR1 mRNA stability (19Lee C.H. Bradley G. Ling V. J. Cell. Physiol. 1998; 177: 1-12Crossref PubMed Scopus (41) Google Scholar), P-glycoprotein turnover (20Zhang W. Ling V. J. Cell. Physiol. 2000; 184: 17-26Crossref PubMed Scopus (36) Google Scholar), or trafficking (21Meschini S. Calcabrini A. Monti E. Del Bufalo D. Stringaro A. Dolfini E. Arancia G. Int. J. Cancer. 2000; 87: 615-628Crossref PubMed Scopus (70) Google Scholar) have been suggested, transcriptional regulation is widely considered to be the key step accounting for the complex spatio-temporal pattern of expression in vivo (22van Kalken C. Giaccone G. van der Valk P. Kuiper C.M. Hadisaputro M.M. Bosma S.A. Scheper R.J. Meijer C.J. Pinedo H.M. Am. J. Pathol. 1992; 141: 1063-1072PubMed Google Scholar, 23Nakayama M. Wada M. Harada T. Nagayama J. Kusaba H. Ohshima K. Kozuru M. Komatsu H. Ueda R. Kuwano M. Blood. 1998; 92: 4296-4307Crossref PubMed Google Scholar). It has also generally been assumed that up-regulation of MDR1 mRNA leads to an increase in P-glycoprotein. For example, human renal carcinoma (16Chin K.V. Tanaka S. Darlington G. Pastan I. Gottesman M.M. J. Biol. Chem. 1990; 265: 221-226Abstract Full Text PDF PubMed Google Scholar) and rat liver cells (24Schrenk D. Gant T.W. Michalke A. Orzechowski A. Silverman J.A. Battula N. Thorgeirsson S.S. Carcinogenesis. 1994; 15: 2541-2546Crossref PubMed Scopus (48) Google Scholar) up-regulate both MDR1 mRNA and P-glycoprotein following different stresses and are consequently transiently resistant to vinblastine. In this study, we show that in K562 leukemic cells the levels ofMDR1 mRNA increase in a dose- and time-dependent manner upon transient exposure to a variety of cytotoxic drugs. However, in contrast to the general prevailing models, we show that this is due to stabilization of mRNA and not because of transcriptional activation. Furthermore, the newly stabilized mRNA is not translated and so does not result in expression of P-glycoprotein and drug efflux. Only on subsequent long-term selection for drug resistance does the stabilized mRNA associate with polyribosomes, permitting translation of P-glycoprotein and drug efflux. The finding that drug resistance is a two-step post-transcriptional process, mediated by changes in bothMDR1 mRNA stability and translation, suggests new possibilities for treatment regimes to circumvent MDR in leukemia. K562, CCRF-CEM, and MANN cells in with and cells K. C.J. Roninson I.B. Gottesman M.M. Pastan I. J. Biol. Chem. 1987; Full Text PDF PubMed Google Scholar) in with and drugs For transient drug cells at 1 and with drug for the The drug to changes in cell of cytotoxic such as and changes in and in greater than of cells. drug for or K562 in a selection by exposure to of the following cytotoxic which had been to result in cell after in in or resistant to of drug and was cells by and by of MDR1 mRNA levels was as C. T.A. B. and Natl. Acad. Sci. U. S. A. 1990; 87: PubMed Scopus Google Scholar). the following the and and for and as by the and with an as the cycle that the a threshold 10 the the was and a was to gene expression. The following was to the of the in the and to an or is the in between the gene of and or and for the of the of the K562, and cells with to inhibit This concentration of was in a of as that which greater than of in both the naı̈ve and K562 cell and 1 B. 1998; PubMed Scopus Google Scholar). at different after and was as or the by an was in In J. T. Scholar) of 10 of the with the or A. M. A. Blood. 1996; 87: PubMed Google Scholar, M. Res. 1990; PubMed Scopus Google Scholar). with a was cells by and with and to by J. T. Scholar). the MDR1 the transcription and K. Pastan I. Gottesman M.M. J. Biol. Chem. 1987; Full Text PDF PubMed Google Scholar) and the locus van G. Cell. Full Text PDF PubMed Scopus Google Scholar). to MDR1 by a or K562 as B. 1998; PubMed Scopus Google Scholar). transcription and have been E. 1994; PubMed Scopus Google Scholar). For transcriptional K562, and cells transiently with the luciferase gene the of S. Scotto K.W. Cell. Biol. 1998; PubMed Google Scholar), with the gene the of the cells and luciferase activity was with a luciferase and expression J. T. Scholar). The luciferase of the to the to rat M. R. J. 1994; PubMed Scopus Google Scholar), was with K562 and cells. cells with the and luciferase and expression as by a gene with cells as J. T. Scholar). of P-glycoprotein expression was by the as B. T. T. Roninson I.B. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar), a cells by of cells and after drug cells after at a of cell by a and cell 1 cells as C. N. Ling V. J. Clin. 1987; 5: PubMed Scopus Google Scholar), with cells with a and at a to and associated such as and The the was at the and by and to at with of the or in was by after with and and of in was by following R. J.A. K. in Scholar). of K562, and MANN and M.J. A.E. Google Scholar). was with and in 10 of ofMDR1 mRNA was by as The myeloid cell K562 levels of MDR1 by by a more mRNA not K562 cells to short-term exposure to different cytotoxic drugs and by MDR1 mRNA levels 1 a to increase in levels in cells with naı̈ve (not exposed to K562 cells not This was due to the cytotoxic drug, because the increase in MDR1 mRNA was both and 1 K562 resistant to levels of cytotoxic drugs with different of and and drug selection in the of resistant of These lines and and MDR1 mRNA was in of lines 1 by to be between and greater than the levels found in the cells not both drug and selection for drug resistance result in in steady-state MDR1 mRNA of the of of the Gene amplification is a common for the up-regulation ofMDR1 mRNA in cell lines (4Gottesman M.M. Pastan I. Annu. Rev. Biochem. 1993; 62: 385-427Crossref PubMed Scopus (3547) Google Scholar) and is by rearrangements and in the and cells had the MDR1gene as the K562, amplification or rearrangements of the locus had MDR1 mRNA up-regulation was due to transcriptional activation P. S. M. G. J. 2000; PubMed Scopus Google Scholar), we two different We a gene in which an was of the luciferase gene S. Scotto K.W. Cell. Biol. 1998; PubMed Google Scholar). This has been to transcriptional activation of MDR1 human carcinoma cells S. Scotto K.W. Cell. Biol. 1998; PubMed Google Scholar). expression was in naı̈ve (not and of the K562 lines that is a in the transcriptional activation of MDR1 Cancer Res. 1999; PubMed Scopus Google Scholar), and because K562 cells resistant to P-glycoprotein have levels and and increased activity Biochem. 1993; PubMed Scopus Google Scholar, Biochem. 1994; PubMed Scopus (33) Google Scholar), was to the that the had been in cells. this we a in which the luciferase gene expression was by human and the rat M. R. J. 1994; PubMed Scopus Google Scholar). This has been in studies because of for the and, as transient in results in an increase of luciferase activity upon activation M. R. J. 1994; PubMed Scopus Google Scholar), which MDR1 gene expression in cell K562 cells P.M. Roninson I.B. Res. 1992; Google Scholar). and cells transiently with levels of luciferase both and after activation the of is in both naı̈ve and K562 and the of transcriptional activation of the MDR1 in cells be due to a of that transcriptional activation of the is not for MDR1 mRNA up-regulation we also the MDR1 in by nuclear the increase in steady-state MDR1 mRNA transcription the MDR1 was with transcription other or and did not increase in or cells not transcriptional activation does not to be for the up-regulation of MDR1 mRNA in K562 cells following drug or upon selection for drug the increase in mRNA was not due to de mRNA we changes in the of mRNA be the of in and we cells with to inhibit transcription MDR1 mRNA naı̈ve K562 cells had a 1 h) by In MDR1 mRNA for and K562 cells This was by and is in with the reported for K562 C. E. I. C. J. G. Google Scholar). K562 cells also had a MDR1 mRNA The of other short-lived such as and to be as reported A. M. A. Blood. 1996; 87: PubMed Google Scholar, M. Res. 1990; PubMed Scopus Google Scholar) in both naı̈ve and K562 cells the of a was also in cells in both naı̈ve K562 and the stabilization of mRNA is and not a general other short-lived In up-regulation ofMDR1 mRNA levels following exposure to after a transient or drug is due to a increase in mRNA exposure to cytotoxic drugs led to an increase in MDR1 mRNA levels mRNA This led to up-regulation was by an increase in P-glycoprotein expression. Cell expression of P-glycoprotein was by the B. T. T. Roninson I.B. Proc. Natl. Acad. Sci. U. S. A. 1997; PubMed Scopus Google Scholar). was increase in cells following drug at the with naı̈ve K562 cells. In cells selected for resistance to the P-glycoprotein or a to increase in the of active P-glycoprotein on the cell selected for resistance to which is not by P-glycoprotein, levels of P-glycoprotein expression than the and mRNA Only of cells P-glycoprotein, with the that resistance to is to be mediated by other P.M. Roninson I.B. J. Natl. Cancer Inst. 1993; 85: 632-639Crossref PubMed Scopus (360) Google Scholar) the active P-glycoprotein in the was to the that P-glycoprotein was in but in the in an form or Cell and K562 cells for P-glycoprotein expression by the of to P-glycoprotein, was in the lines but not the naı̈ve or cells P-glycoprotein was also nuclear and of that the was not The of the was with the of and cells MDR1 cells are to P-glycoprotein transient treatment with cytotoxic drugs led to cell cycle was to the that of cell cycle was for the to P-glycoprotein. The was because activity can be following of the cells PubMed Scopus Google Scholar). K562 cells for with which the cell cycle and MDR1 mRNA and The cells to for a at the as cells The increase in MDR1 mRNA for at after drug this did not to the of P-glycoprotein is not for the of P-glycoprotein expression in cells. This was by cells as resistant to the substrate both and not by that the MDR1 was in both of cells not cell selected for resistance to and can also but to P-glycoprotein. cells that cycle after drug or after selection with a can mRNA but to P-glycoprotein. the absence of P-glycoprotein expression in cells was a to K562 we the acute lymphocytic cell In contrast to K562 naı̈ve cells found to have MDR1 mRNA which increased upon drug P-glycoprotein was in the cells not We also a cell the cell in which the naı̈ve cells levels of MDR1 mRNA but P-glycoprotein to not These cells are also to efflux a P-glycoprotein substrate C. S. 1992; 23: PubMed Scopus Google Scholar). The of correlation between steady-state MDR1 mRNA and P-glycoprotein levels in cell lines suggests that the P-glycoprotein expression is not restricted to K562 cells. the MDR1 mRNA had or that the cells was and with the in the to in the MDR1 a K562 cell P-glycoprotein between the mRNA that mRNA does not or short-term drug or drug which for of P-glycoprotein. can have a general on Biochem. Sci. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar, I. Y. H. R. M. D. Cell. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar, U. C. H. Cell. Biol. 2001; PubMed Scopus Google Scholar) we also the of of in naı̈ve and K562 cells. was an in the of after in the of cytotoxic drug, which to after not upon treatment with cytotoxic drugs is a general in the of synthesis. However, translation is by the drug this is to for the of expression of P-glycoprotein. that the absence of P-glycoprotein expression in cells was due to a to we MDR1 mRNA with Cell by and the of in was by G. C. P.A. J. Biol. Chem. 2000; 275: Full Text Full Text PDF PubMed Scopus Google Scholar). In a ofMDR1 mRNA was associated with polyribosomes the of the that mRNA was by in the and the of the MDR1 mRNA the of the as In for K562 cells MDR1 mRNA at the as for cells of the that in cells is not associated with polyribosomes and is not translated the that the absence of between and polyribosomes is due to a general in the of by the cytotoxic the ofMDR1 mRNA with was also in cell In which had not been exposed to cytotoxic mRNA was not associated with polyribosomes The translational block therefore, not due to the of cytotoxic drugs and a for P-glycoprotein expression. of in leukemia has been with the clinical to chemotherapy (2McKenna S.L. Padua R.A. Br. J. Haematol. 1997; 96: 659-674Crossref PubMed Scopus (77) Google Scholar, 3Ivy S.P. Olshefski R.S. Taylor B.J. Patel K.M. Reaman G.H. Blood. 1996; 88: 309-318Crossref PubMed Google Scholar, A. N. T. P. Br. J. Haematol. 1998; PubMed Scopus Google Scholar). We have a K562 leukemic cell to the MDR1 gene expression in the of Unexpectedly, we found that in up-regulation of P-glycoprotein expression was a two-step process, mRNA stabilization and a translational K562 cell lines resistant to the P-glycoprotein and or to the In contrast to many we lines by a selection to of cytotoxic drug, than the selection at drug This to at drug and levels of drug resistance to found in the and amplification and rearrangements of locus frequently found in resistant cell lines but in vivo (1Gottesman M.M. Fojo T. Bates S.E. Nat. Rev. Cancer. 2002; 2: 48-58Crossref PubMed Scopus (4443) Google Scholar). K562 as as naı̈ve K562 cells transiently exposed to a range of cytotoxic steady-state MDR1 mRNA levels 1 This was of the of of the has been reported that or also MDR1 gene expression in a variety of P. S. M. G. J. 2000; PubMed Scopus Google Scholar). activation is generally assumed to be the for MDR1 gene and regulatory have been and characterized in the P. S. M. G. J. 2000; PubMed Scopus Google Scholar). In this we found that in K562 leukemic cells transiently exposed to drugs or selected for drug resistance the increased MDR1 mRNA levels not be for by transcriptional activation of the Furthermore, the activation of the MDR1 in other cell was not in K562 cells the that the activation by was to be in both naı̈ve and K562 cells K562 cells not the gene G.H. Res. 1993; PubMed Scopus Google Scholar), the absence of transcriptional activation in the cells at in be due to a of which is to activate the MDR1 M.E. E. Cowan K.H. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). In contrast to transcriptional we found that up-regulation of MDR1 mRNA in K562 cells is due to an increase in mRNA stability and This was to the MDR1 mRNA as the stability of other short-lived mRNA in naı̈ve K562 MDR1 mRNA has a 1 in to the of transcription the MDR1 can for the steady-state levels found in naı̈ve cells The in mRNA stabilization are but not in the of the C.J. M. Nat. Rev. Cell. Biol. 2001; 2: PubMed Scopus Google Scholar). The is and that mRNA C.J. M. Nat. Rev. Cell. Biol. 2001; 2: PubMed Scopus Google Scholar). The of in naı̈ve K562 cells with the studies that a in the human cell A. C. Biochem. Res. 1999; PubMed Scopus Google Scholar). The MDR1 mRNA increased upon transient exposure of cells to cytotoxic drugs and in the lines and have also been in a K562 resistant to C. E. I. C. J. G. Google Scholar). The stabilized MDR1 mRNA K562 cells for after the the cytotoxic but to the of naı̈ve K562 cells with of a upon cell to levels a of the is that this is upon drug exposure. In contrast to other studies different (16Chin K.V. Tanaka S. Darlington G. Pastan I. Gottesman M.M. J. Biol. Chem. 1990; 265: 221-226Abstract Full Text PDF PubMed Google Scholar, D. Gant T.W. Michalke A. Orzechowski A. Silverman J.A. Battula N. Thorgeirsson S.S. Carcinogenesis. 1994; 15: 2541-2546Crossref PubMed Scopus (48) Google Scholar), following transient drug exposure the increase in steady-state MDR1 mRNA was not by a increase in P-glycoprotein expression in K562 cells This in be due to a in the of due to cytotoxic by the drug Biochem. Sci. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar, I. Y. H. R. M. D. Cell. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar, U. C. H. Cell. Biol. 2001; PubMed Scopus Google but P-glycoprotein, was also in K562 cells after and in K562 cells resistant to the substrate not In cells and human not P-glycoprotein not of correlation expression and P-glycoprotein has also been reported in acute myeloid leukemia cell lines C. C. G. C. G. Google Scholar) and human lymphoid cells P.M. Roninson I.B. Cell. Full Text PDF PubMed Scopus Google Scholar). therefore, a of correlation between the of MDR1 mRNA and P-glycoprotein in cell models, is not to K562 cells or the drug treatment In this we show that translational regulation an in the levels of P-glycoprotein expression. most at the of because MDR1 mRNA does not with the in cells. the ofMDR1 mRNA and cells is regulation A.E. Int. J. Biochem. Cell Biol. 1999; PubMed Scopus Google Scholar, J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). drug selection this translational block is the cells to in the of the cytotoxic In the show that in K562 cells up-regulation ofMDR1 gene expression at two steps, mRNA stabilization and translational two steps are distinct is also by with a cytotoxic drug not by P-glycoprotein. was as as the P-glycoprotein in MDR1 mRNA that this is a general to selection for resistance, P-glycoprotein was in a of in contrast to selection for resistance to P-glycoprotein cells P-glycoprotein MDR1 mRNA was in both the and cells not that in cells the step in the of MDR has The the translational had also in a of cells. M.J. E. Proc. Natl. Acad. Sci. U. S. A. 1998; PubMed Scopus Google Scholar), and are in K562 and cells Cell Res. 2000; PubMed Scopus Google Scholar), the expression of P-glycoprotein in this of cells that P-glycoprotein a of These findings have implications for to circumvent or overcome drug resistance in the at for leukemia. the that MDR1 mRNA levels not with P-glycoprotein expression show that mRNA as a clinical for drug resistance is as drugs can stabilization of MDR1 the step in drug resistance, drug treatment regimes be to this as of drug resistance two steps, stabilization of MDR1 mRNA and subsequent of a translational of steps and for drug resistance in the clinic. We Scotto and for the of and for with and and for

References

55